Feng, Xiaodong_ Xie, Hong-Guang - Applying pharmacogenomics in therapeutics-CRC Press (2016)

Essential Pharmacogenomic Biomarkers in Clinical Practice
71
82. Rizzardini G, Zucchi P. Abacavir and lamivudine for the treatment of human immunodeficiency
virus. Expert Opinion on Pharmacotherapy 2011;12:2129–38.
83. Hughes CA, Foisy MM, Dewhurst N, et al. Abacavir hypersensitivity reaction: An
update. The Annals of Pharmacotherapy 2008;42:387–96.
84. Cruciani M, Zanichelli V, Serpelloni G, et al. Abacavir use and cardiovascular disease
events: A meta-analysis of published and unpublished data. AIDS (London, England)
2011;25:1993–2004.
85. Costagliola D, Lang S, Mary-Krause M, Boccara F. Abacavir and cardiovascular risk:
Reviewing the evidence. Current HIV/AIDS Reports 2010;7:127–33.
86. Hughes AR, Spreen WR, Mosteller M, et al. Pharmacogenetics of hypersensitivity
to abacavir: From PGx hypothesis to confirmation to clinical utility. The
Pharmacogenomics Journal 2008;8:365–74.
87. Saag M, Balu R, Phillips E, et al. High sensitivity of human leukocyte antigen-b*5701
as a marker for immunologically confirmed abacavir hypersensitivity in white and
black patients. Clinical Infectious Diseases 2008;46:1111–8.
88. McPhail GL, Clancy JP. Ivacaftor: The first therapy acting on the primary cause of
cystic fibrosis. Drugs Today (Barc) 2013;49:253–60.
89. Accurso FJ, Rowe SM, Clancy JP, et al. Effect of VX-770 in persons with cystic fibrosis
and the G551D-CFTR mutation. The New England Journal of Medicine 2010;​
363:1991–2003.
90. Davies JC, Wainwright CE, Canny GJ, et al. Efficacy and safety of ivacaftor in patients
aged 6 to 11 years with cystic fibrosis with a G551D mutation. American Journal of
Respiratory and Critical Care Medicine 2011;187:1219–25.
91. Flume PA, Liou TG, Borowitz DS, et al. Ivacaftor in subjects with cystic fibrosis who
are homozygous for the F508del-CFTR mutation. Chest 2012;142:718–24.
92. Sermet-Gaudelus I. Ivacaftor treatment in patients with cystic fibrosis and the G551D-
CFTR mutation. European Respiratory Review 2013;22:66–71.
93. Harrison MJ, Murphy DM, Plant BJ. Ivacaftor in a G551D homozygote with cystic
fibrosis. The New England Journal of Medicine 2013;369:1280–2.
94. Labianca R, Sarzi-Puttini P, Zuccaro SM, Cherubino P, Vellucci R, Fornasari D.
Adverse effects associated with non-opioid and opioid treatment in patients with
chronic pain. Clinical Drug Investigation 2012;32(Suppl 1):53–63.
95. Crews KR, Gaedigk A, Dunnenberger HM, et al. Clinical Pharmacogenetics Implementation
Consortium (CPIC) guidelines for codeine therapy in the context of cytochrome P450 2D6
(CYP2D6) genotype. Clinical Pharmacology and Therapeutics 2012;91:321–6.
96. Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance:
Part I. Clinical Pharmacokinetics 2009;48:689–723.
97. Lotsch J, Rohrbacher M, Schmidt H, Doehring A, Brockmoller J, Geisslinger G. Can
extremely low or high morphine formation from codeine be predicted prior to therapy
initiation? Pain 2009;144:119–24.
98. VanderVaart S, Berger H, Sistonen J, et al. CYP2D6 polymorphisms and codeine analgesia
in postpartum pain management: A pilot study. Therapeutic Drug Monitoring
2011;33:425–32.
99. Wu X, Yuan L, Zuo J, Lv J, Guo T. The impact of CYP2D6 polymorphisms on the pharmacokinetics
of codeine and its metabolites in Mongolian Chinese subjects. European
Journal of Clinical Pharmacology 2014;70:57–63.
100. Pacher P, Nivorozhkin A, Szabo C. Therapeutic effects of xanthine oxidase inhibitors:
Renaissance half a century after the discovery of allopurinol. Pharmacological
Reviews 2006;58:87–114.
101. Lee HY, Ariyasinghe JT, Thirumoorthy T. Allopurinol hypersensitivity syndrome:
A preventable severe cutaneous adverse reaction? Singapore Medical Journal 2008;​
49:384–7.